288 studies found for:    Open Studies | "Parasitic Diseases"
Show Display Options
Rank Status Study
21 Unknown  Randomized Trial of Erythropoietin During Cerebral Malaria
Condition: Cerebral Malaria
Interventions: Drug: Placebo;   Drug: Erythropoietin
22 Unknown  Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
Condition: Neurocysticercosis
Interventions: Drug: Albendazole;   Drug: Dexamethasone;   Drug: Omeprazole
23 Recruiting Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Condition: Toxoplasmosis
Interventions: Drug: Leucovorin calcium;   Drug: Pyrimethamine;   Drug: Spiramycin;   Drug: Sulfadiazine
24 Recruiting Treatment of Patients With Cysticercosis With Praziquantel or Albendazole
Condition: Cysticercosis
Intervention:
25 Recruiting Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)
Condition: Wuchereria Bancrofti Infection
Intervention: Drug: Ivermectin, Diethylcarbamazine Albendazole (IDA)
26 Recruiting Asymptomatic Leishmania Infection in HIV Patients
Condition: Visceral Leishmaniasis
Intervention:
27 Not yet recruiting Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
Conditions: Hookworm Disease;   Hookworm Infection
Interventions: Biological: Na-GST-1/Alhydrogel;   Biological: Na-APR-1 (M74)/Alhydrogel;   Biological: Hepatitis B Vaccine
28 Recruiting Controlled Human Malaria Infection Model for Evaluation of Transmission‐Blocking Interventions - Study 1
Condition: Malaria
Interventions: Drug: Sulfadoxine-pyrimethamine (low dose);   Drug: Piperaquine (low dose);   Drug: Sulfadoxine-pyrimethamine (high dose);   Drug: Piperaquine (high dose);   Biological: malaria challenge infection, P. falciparum 3D7;   Drug: Atovaquone-proguanil
29 Not yet recruiting "Performance of HPV DNA Test in Presence of Co-infection With Common RTIs"
Condition: Cervical Inflammation and Human Papilloma Virus Performance
Intervention: Drug: Tab cefixime,Tab Azithromycin
30 Recruiting An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)
Condition: Schistosomiasis
Interventions: Drug: Biltricide (racemate praziquantel) oral tablets;   Drug: Racemate Praziquantel ODT;   Drug: Levo Praziquantel ODT
31 Not yet recruiting Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
Condition: Malaria, Vivax
Interventions: Drug: Tafenoquine;   Drug: Matched-Placebo for Tafenoquine;   Drug: Primaquine;   Drug: Matched-Placebo for Primaquine;   Drug: Dihydroartemisinin-piperaquine (DHA-PQP);   Drug: ACT plus PQ (Rescue medication);   Drug: PQ (End of study treatment)
32 Not yet recruiting Child Follow-up Until 2 Years
Conditions: Malaria;   Pregnancy
Intervention:
33 Not yet recruiting Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
Condition: Malaria
Interventions: Drug: Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy;   Drug: Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy
34 Not yet recruiting Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Condition: Malaria
Intervention:
35 Recruiting Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers
Condition: Malaria
Interventions: Drug: Arterakine (DHA/piperaquine);   Drug: Placebo
36 Not yet recruiting A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)
Condition: Uncomplicated Malaria
Interventions: Drug: PQ supervised;   Drug: PQ unsupervised
37 Recruiting Plasmodium Immunotherapy for Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Biological: Blood-stage infection of P. vivax
38 Recruiting MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B
Condition: Malaria
Interventions: Drug: MMV390048 40mg;   Drug: MMV390048 dose to be determined mg
39 Recruiting Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
Condition: Malaria
Interventions: Drug: MMV390048 40 mg;   Drug: Placebo to match MMV390048 40 mg;   Drug: MMV390048 80 mg;   Drug: Placebo to match MMV390048 80 mg;   Drug: MMV390048 120 mg;   Drug: Placebo to match MMV390048 120 mg
40 Not yet recruiting PfSPZ Challenge in Non-immune Adults in Baltimore, USA
Condition: Plasmodium Falciparum Infection
Interventions: Biological: PfSPZ (NF54);   Biological: PfSPZ (7G8)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years